

Efficacy of low dose atropine to reduce myopia progression among Indian children

Dear Editor,

The prevalence of myopia across the globe continues to increase at an alarming rate and it is estimated that almost half of the world's population will be myopic by the year 2050, with 10% of them being highly myopic ^[1]. Following a similar trend to the worldwide data, the prevalence of myopia among school children in India has increased from 5.6% in 2002^[2] to 13.1 % in 2015^[3]. Minimising the degree of myopia is important as greater myopia, 6 dioptres or more, is associated with an increased incidence of ocular pathology such as myopic degeneration, retinal detachment and glaucoma ^[4], however, recently it has been shown that even low and moderate levels of myopia increase the risk of pathology ^[5]. Finding an effective and safe way to reduce the progression of myopia early in life is becoming increasingly important.

A recent meta-analysis of myopia interventions including atropine, orthokeratology, outdoor exposure, spectacle correction, contact lens correction of refractive error, showed atropine to be the most effective ^[6]. The ATOM 2 study was conducted to test if lower concentrations (0.5%, 0.1% and 0.01%) of atropine could have a similar efficacy as 1% atropine. The overall progression of myopia was lower in the 0.01% atropine group (-0.72 ± 0.72 D) followed by the 0.1% atropine group (-1.04 ± 0.83 D) with the highest progression noted in children who were treated with 0.5% atropine (-1.15 ± 0.81 D) at the end of 3-years period ^[7]. The Low-Concentration Atropine for Myopia Progression (LAMP) study demonstrated mean myopia progression of 0.27D, 0.46D, 0.59D and 0.81D over 1 year, for participants allocated with 0.05%, 0.025% and 0.01% compared to placebo, with a mean increase in axial length of 0.20 mm, 0.29 mm, 0.36 mm and 0.41 mm respectively. It was concluded that, all concentrations

were well tolerated without any adverse effects and of the three concentrations used, 0.05% atropine was the most effective in controlling the progression and axial length elongation over a period of 1 year [8].

Recently the I-Atom study group published results from a randomized clinical trial showing that 0.01% atropine is found to be effective in controlling myopia by 54% among Indian children, but interestingly there was no statistically significant difference in axial length [9].

There are a number of ethical issues and practical challenges in conducting a placebo-controlled trial of 0.01% atropine in India as it is a licensed drug, so an open trial was conducted to investigate the efficacy of low dose (0.01%) atropine in children recruited from a tertiary eye care centre in south India.

After treatment for one year with 0.01% atropine the mean rate of progression of myopia (RMP – Difference between current visit cycloplegic spherical equivalent (SE) and previous year visit cycloplegic SE) was 0.41 D/year and 0.45 D/year in the right and left eye respectively, as opposed to 0.93 D/year and 0.93 D/year before treatment (Figure 1). The mean increase in the axial length was 0.18 mm and 0.25 mm in the right and left eye respectively after treatment. Among the 60 children, 50 (83.33%) of them responded to the treatment, whereas 10 (16.67%) of them showed a progression of > 0.50 D despite treatment. Table 1 shows the mean spherical equivalent and axial length at baseline and at one-year.

Among the 60 children, 3 (5%) of them had mild stinging (reported once) immediately after the instillation of the eye drops, however it was temporary. No participants had reading difficulties or any complaints of photophobia or glare. Visual acuity, accommodation and ocular surface were all unaffected by treatment.

In this study, the increases in axial length do not correlate with the change in refraction and require further study for better understanding. Ten participants had significant myopia progression despite treatment with 0.01% atropine. In these non-responders, an approach with a higher dose of atropine or a combined strategy with other optical treatments could be attempted.

Atropine treatment has now been incorporated into clinical practice in India and shows real promise as a treatment for controlling myopia, however, future studies are required to investigate the mechanism of action of the low-dose atropine and the disparity between refractive error and axial length data during treatment.

Moreover, an optimal management strategy for non-responders remains unclear. Although, some of the evidence suggests using a combination of optical and pharmacological treatments, further studies are needed to test the efficacy of a combination of treatment modalities. Additional work is needed to address some areas of uncertainty, for example, best time to start and stop treatment.

Acknowledgments: Dr. Surendran T S, Dr. Sumita Agarkar, Dr. Kavitha Kalaivani, Dr. Akila Ramkumar V, Dr. Muthu Meena Muth Malai for providing medical care through the Paediatric-ophthalmology department.

References:

1. Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P et al., Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. *Ophthalmol* 2016 ;123:1036-42.
2. Dandona R, Dandona L, Srinivas M, Sahare P, Narsaiah S, Munoz SR et al. Refractive error in children in a rural population in India. *Invest Ophthalmol Vis Sci* 2002 ;43:615-22.
3. Saxena R, Vashist P, Tandon R, Pandey RM, Bhardawaj A, Menon V et al., Prevalence of myopia and its risk factors in urban school children in Delhi: the North India Myopia Study (NIM Study). *PloS one* 2015;10: e0117349.

4. Flitcroft DI. The complex interactions of retinal, optical and environmental factors in myopia aetiology. *Prog Retin Eye Res* 2012;31:622-60.
5. Haarman AE, Enthoven CA, Tideman JW, Tedja MS, Verhoeven VJ, Klaver CC. The Complications of Myopia: A Review and Meta-Analysis. *Invest Ophthalmol Vis Sci* 2020;61:49-49.
6. Ernie Bowling OD. Safety and efficacy of myopia progression therapies in children. *Optometry Times* 2020; 12:28-28.
7. Chia A, Chua WH, Cheung YB, Wong WL, Lingham A, Fong A et al., Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). *Ophthalmol* 2012 1; 119:347-54.
8. Yam JC, Jiang Y, Tang SM, Law AK, Chan JJ, Wong E et al., Low-concentration atropine for myopia progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control. *Ophthalmol* 2019; 126:113-24.
9. Saxena R, Dhiman R, Gupta V, Kumar P, Matalia J, Roy L et al., Atropine for treatment of childhood myopia in India (I-ATOM): multicentric randomized trial. *Ophthalmology* 2021.

Table 1. Mean Spherical Equivalent (SE) and Axial length at baseline and at one year.

	Spherical Equivalent (OD) (Range)	Spherical Equivalent (OS) (Range)	Axial Length (OD) (Range)	Axial Length (OS) (Range)
Baseline	-4.90±1.98 (-2.00 / -11.88) (RMP** 0.93D)	-4.76±1.95 (-2.00 / -12.12) (RMP** 0.93D)	25.16±0.99 (23.01 / 28.02)	25.11±1.01 (23.02 / 28.07)
1yr follow up	-5.49±1.98 (RMP** 0.41D)	-5.31±1.80 (RMP** 0.45D)	25.43±1.05	25.42±1.03
p-value*	< 0.001	< 0.001	< 0.001	< 0.001

* paired t-test

**RMP – Rate of myopia progression calculated as difference between current visit cycloplegic SE and previous year visit cycloplegic SE.